Abstract:In polypharmacology, ideal drugs are required to bind to multiple specific targets to enhance efficacy or to reduce resistance formation. Although deep learning has achieved breakthrough in drug discovery, most of its applications only focus on a single drug target to generate drug-like active molecules in spite of the reality that drug molecules often interact with more than one target which can have desired (polypharmacology) or undesired (toxicity) effects. In a previous study we proposed a new method named DrugEx that integrates an exploration strategy into RNN-based reinforcement learning to improve the diversity of the generated molecules. Here, we extended our DrugEx algorithm with multi-objective optimization to generate drug molecules towards more than one specific target (two adenosine receptors, A 1 AR and A 2A AR, and the potassium ion channel hERG in this study). In our model, we applied an RNN as the agent and machine learning predictors as the environment , both of which were pre-trained in advance and then interplayed under the reinforcement learning framework. The concept of evolutionary algorithms was merged into our method such that crossover and mutation operations were implemented by the same deep learning model as the agent . During the training loop, the agent generates a batch of SMILES-based molecules. Subsequently scores for all objectives provided by the environment are used for constructing Pareto ranks of the generated molecules with non-dominated sorting and Tanimoto-based crowding distance algorithms. Here, we adopted GPU acceleration to speed up the process of Pareto optimization. The final reward of each molecule is calculated based on the Pareto ranking with the ranking selection algorithm. The agent is trained under the guidance of the reward to make sure it can generate more desired molecules after convergence of the training process. All in all we demonstrate generation of compounds with a diverse predicted selectivity profile toward multiple targets, offering the potential of high efficacy and lower toxicity.

Artificial intelligence in multi-objective drug design

Multi-objective optimization methods in novel drug design

Integrating transformers and many-objective optimization for drug design

Multi-and many-objective optimization: present and future in de novo drug design

Artificial Intelligence in De novo Drug Design: Are We Still There?

A comprehensive review of molecular optimization in artificial intelligence‐based drug discovery

Artificial intelligence in drug discovery: recent advances and future perspectives

Guided Multi-objective Generative AI to Enhance Structure-based Drug Design

Advances in De Novo Drug Design: From Conventional to Machine Learning Methods

DrugEx V2: De Novo Design of Drug Molecules by Pareto-based Multi-Objective Reinforcement Learning in Polypharmacology

An Artificial Intelligence Framework for Optimal Drug Design

Advances of AI-driven Drug Design and Discovery in Pharmaceuticals - Review

Overcoming DMTA Cycle Challenges: A Unified AI-Driven System for Efficient Drug Design

Artificial intelligence to deep learning: machine intelligence approach for drug discovery

Exploring the Artificial Intelligence and Machine Learning Models in the Context of Drug Design Difficulties and Future Potential for the Pharmaceutical Sectors

A Survey of Generative AI for de novo Drug Design: New Frontiers in Molecule and Protein Generation

Evaluation Framework for AI-driven Molecular Design of Multi-target Drugs: Brain Diseases as a Case Study

Human-in-the-loop assisted de novo molecular design

Computer-aided multi-objective optimization in small molecule discovery

The Process of AI-Aided Drug Design